What Do Wall Street Analysts Think of Illumina?

This morning we watched Illumina drop -1.9% to a price of $139.77 per share. The large-cap Medical Specialities company is now trading -34.63% below its average target price of $213.82. Analysts have set target prices ranging from $125.0 to $318.0 per share for Illumina, and have given the stock an average rating of hold.

Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.0%. The stock's short ratio is 4.38. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 93.5%. In conclusion, we believe there is mixed market sentiment regarding Illumina.

Institutions Invested in Illumina

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 10% 15,630,823 $2,184,720,197
2023-06-30 Baillie Gifford and Company 9% 13,973,317 $1,953,050,576
2023-06-30 Blackrock Inc. 9% 13,464,324 $1,881,908,623
2023-06-30 Morgan Stanley 5% 7,544,967 $1,054,560,069
2023-06-30 State Street Corporation 4% 6,715,664 $938,648,385
2023-06-30 Edgewood Management Llc 4% 5,572,973 $778,934,460
2023-06-30 Wellington Management Group, LLP 3% 5,275,549 $737,363,506
2023-06-30 Polen Capital Management, LLC 3% 5,097,461 $712,472,145
2023-06-30 Janus Henderson Group PLC 3% 4,783,774 $668,628,112
2023-06-30 Loomis Sayles & Company, LP 2% 3,799,690 $531,082,687
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.